The Role of Interleukins 4 and/or 13 in the Pathophysiology and Treatment of Atopic Dermatitis

Jonathan I. Silverberg*, Robert Kantor

*Corresponding author for this work

Research output: Contribution to journalReview article

19 Scopus citations

Abstract

Moderate to severe atopic dermatitis (AD) can be debilitating and often requires use of systemic immunosuppressant therapy to achieve adequate disease control. There are currently no US Food and Drug Administration–approved systemic agents for the long-term treatment of AD. Recent insight has identified the T helper 2 cytokines, interleukins 4 and 13, as playing a major role in the pathogenesis of AD. There are multiple novel biologic agents in development that target interleukins 4 and/or 13 for the treatment of moderate to severe AD. The age of targeted biologics for AD has arrived.

Original languageEnglish (US)
Pages (from-to)327-334
Number of pages8
JournalDermatologic clinics
Volume35
Issue number3
DOIs
StatePublished - Jul 2017

Keywords

  • Atopic dermatitis
  • Biologic
  • Eczema
  • Inflammation
  • Interleukin 13
  • Interleukin 4
  • T helper 2

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'The Role of Interleukins 4 and/or 13 in the Pathophysiology and Treatment of Atopic Dermatitis'. Together they form a unique fingerprint.

  • Cite this